Davion Healthcare Plc filed a Form 6-K on October 27, 2026, reporting the October 26, 2026 completion of its acquisition of intellectual property and associated assets relating to WoundSkan and the Spektra Lateral Flow Test from four individual sellers under an agreement dated September 21, 2026.

Key Highlights

  • Total consideration: US$25 million, comprising US$2.5 million in cash and 1,730,770 new ordinary shares of EUR0.01 each at an agreed contractual value of US$13.00 per share, representing approximately US$22.5 million.
  • Sellers: R. Kisiel, S. Dickson, A. Baker, and P. Fortune, under an Intellectual Property Sale and Purchase Agreement dated September 21, 2026.
  • Cash payment deadline: The US$2.5 million cash consideration is payable no later than 120 calendar days following commencement of Nasdaq trading, with a Seller cancellation right if unpaid.
  • Deferred share issuance: The 1,730,770 consideration shares are to be issued on the first Business Day following expiration of a 90-calendar-day deferred issuance period; Sellers hold no shareholder rights before issuance.
  • Leak-out restriction: Following issuance, each Seller is subject to a 90-calendar-day contractual leak-out period limiting daily disposals to no more than 10% of the average Nasdaq trading volume over the immediately preceding five trading days.
  • Scope of acquisition: The transaction covers intellectual property and associated assets only; the company is not acquiring Humaskan Ltd, shares in Humaskan Ltd, or its employees, and assumes no pre-completion liabilities of Humaskan Ltd or any Seller except as expressly provided in the Agreement.

Davion Healthcare Completes Humaskan IP Acquisition, Outlines Payment and Issuance Terms

According to the filing, completion of the acquisition occurred automatically on the first Business Day immediately following commencement of trading of the company's ordinary shares on Nasdaq. The acquired assets include WoundSkan, described in the filing as "a battery-free, smartphone-read wound-temperature monitoring dressing," and the Spektra Lateral Flow Test, described as "a rapid multi-marker screening platform." The associated assets transferred also include technical documentation, software, development and testing data, regulatory materials, prototypes, and know-how, as described in the Agreement.

The filing specifies that the agreed share count of 1,730,770 does not vary with market-price movements but is subject to equitable adjustment for specified capital reorganisations. Overdue cash payments bear interest as specified in the Agreement. Davion disclosed that it intends, subject to eligibility and applicable law, to provide effective registration coverage for the issuance of the consideration shares. The filing notes that if such coverage is unavailable, "the parties are to cooperate with their legal advisers to implement a lawful alternative mechanism."

The filing was signed by Glenn Williams, Chief Executive Officer of Davion Healthcare Plc (NASDAQ:DAVI), on October 27, 2026. The company's principal executive office is located at Unit A, West Cork Business and Technology Park, Clonakilty, County Cork, Ireland. The filing confirmed that Davion files annual reports under Form 20-F as a foreign private issuer.

What Was Disclosed

Davion Healthcare Plc reported completion of its acquisition of the WoundSkan and Spektra Lateral Flow Test intellectual property and related assets for total consideration of US$25 million, split between a US$2.5 million cash payment and 1,730,770 new ordinary shares valued contractually at US$13.00 each.